MHRA Drug Safety Update Dec 2020
- Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk
- Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
You can sign up to receive these alerts directly from the MHRA at: MHRA email alerts
Published: 11/01/2021. Medicines Update blogs are correct at the time of publication.